Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction

Next Previous
X
Search
Trial Profile

Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTH 120 (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms FIH-CTH120
  • Sponsors Connecta Therapeutics

    • Most Recent Events

    • 01 Jul 2024 Status changed from planning to recruiting.
    • 06 Jun 2023 According to a Connecta Therapeutics media release, the Spanish Agency of Me=dicines and Medical Devices (AEMPS) has granted authorization to start this trial which will take place at Hospital del Mar Research Institute in Barcelona with Dr Rafael de la Torre and Dr Ana Aldea as principal investigator. Results from study are expected in the second quarter of 2024.
    • 12 Aug 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top